Table 4.
Cost effectiveness analysis in base case
| Mean differences (95% CI) and ICERs | |||
|---|---|---|---|
| Effect | All patients (n = 73: CBT 37 vs TAU 36) | Moderate/severe patients (n = 50: CBT 24 vs TAU 26) | |
| Incremental costs | (JPY) | 97 297 (43 818 to 149 761) | 84 315 (28 718 to 144 589) |
| (USD) | 905 (408 to 1394) | 785 (267 to 1346) | |
| Incremental QALY gain | −0.006 (−0.077 to 0.065) | 0.042 (−0.049 to 0.126) | |
| ICER | (JPY per QALY) | −15 278 322 | 2 026 865 |
| (USD per QALY) | −142 184 | 18 863 | |
These values were estimated in complete samples.
CI, confidence intervals; ICER, Incremental cost effectiveness ratio; JPY, Japanese yen; QALY, quality adjusted life years; USD, United States dollars.